Cabaletta Bio, INC 8-K filings
NASDAQ
Cabaletta Bio reports positive initial clinical data from its Phase 1/2 trials of CABA-201, showing promising results in patients with myositis and lupus.
NASDAQ
Cabaletta Bio held its 2024 Annual Meeting of Stockholders, electing two Class II directors and ratifying Ernst & Young LLP as its independent auditor for the fiscal year ending December 31, 2024.
NASDAQ
Cabaletta Bio announced its first quarter 2024 financial results and provided a business update, highlighting positive initial safety data from its CABA-201 trials and advancements in its clinical programs.
NASDAQ
Cabaletta Bio announced its fourth quarter and full year 2023 financial results, highlighting clinical trial advancements and a cash runway into the first half of 2026.
NASDAQ
8-K: Cabaletta Bio Receives FDA Orphan Drug Designation for CABA-201 in Systemic Sclerosis Treatment
Cabaletta Bio has been granted Orphan Drug Designation by the FDA for its CABA-201 therapy, aimed at treating systemic sclerosis.
NASDAQ
Cabaletta Bio has been granted Orphan Drug Designation by the FDA for its CABA-201 therapy, aimed at treating idiopathic inflammatory myopathies (myositis).